Serkan Sertel, Peter K. Plinkert and Thomas Efferth Pages 849 - 854 ( 6 )
The epidermal growth factor receptor (EGFR) has become an important molecular target in cancer therapy. Various small molecules and therapeutic antibodies targeting EGFR family members have been developed during recent years and are established in clinical oncology. However, increasing clinical application of EGFR tyrosine kinase inhibitors has resulted in the development of resistance to EGFR-targeting drugs due to the selection of EGFR-mutated variants. This phenomenon forced the search for novel EGFR inhibitors with activity towards EGFR-mutant tumors. This review describes recent achievements in natural products derived from medicinal plants as novel EGFR inhibitors.
Cancer, drug resistance, epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitor, medicinal plant, natural product, head and neck squamous cell cancer, HNSCC, renal cancer, ovarian cancer, vinblastine, vincristine, paclitaxel, camptothecin, Cephalotaxus hainanensis, cephalotaxine, CET, ester homoharringtonine, Artemisia annua, Magnolia officinalis, small cell carcinoma, SCC, non-small cell carcinoma, small cell lung carcinoma, SCLC, cell lung carcinoma, NSCLC, Oral squamous cell carcinoma, OSCC, Magnoliae Cortex, CPT, Lithospermum erythrorhizon, Rabdosia rubescens, Lithospermum radix
Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Staudingerweg 5, D-55128 Mainz, Germany.